Evaluation of Serum level of thrombomodulin in cases with preeclampsia

Abstract Background Preeclampsia is a multisystmic disorder of unknown cause. Endothelial cell damage has recently been suggested to underlie the pathologic change in preeclamptic pregnancy. Thrombomodulin an endothelial cell surface glycoprotein act as a co-factor for thrombin catalyzed activation of protein C. activated protein C inhibits coagulation by inactivation the coagulation factor Va and VIIIa. Aim of the Work to assess the changes in thrombomodulin level in women with preeclampsia. Patients and Methods This prospective case-control study was conducted on 123 women at Ain Shams University Maternity Hospital. Results Regarding clinic-pathological features of pre-eclampsia patients and healthy control groups, our study found that there was high significant difference (p ≤ 0.01) between hypertensive and normal patients regarding (hypertension, obesity and history of PET). Our study found that there was high significant difference (p ≤ 0.01) between pre-eclampsia patients and healthy control group regarding serum thrombomodulin protein level and serum thrombomodulin protein increases significantly with mild and severe preeclampsia and HELLP syndrome and considered a good marker for evaluation of hypertensive patients with pregnancy. Conclusion serum thrombomodulin protein level is considered a good marker for evaluation of hypertensive patients with pregnancy.